Payment overview · 2025
General Payments
$1,710.14
91 reported records · 23 companies
Healthcare provider profile · identity verified
Christopher Edward Bowman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HURRICANE, WV · NPI 1649231606
Verified facts
What the public records show
CMS Open Payments records show Christopher Edward Bowman, MD received $1,710.14 in general payments during 2025 across 91 reported records.
Novo Nordisk Inc accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 332 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 332 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1285 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $365.79 | 21.4% | 18 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $213.82 | 12.5% | 18 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $186.67 | 10.9% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.37 | 9.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $107.46 | 6.3% | 6 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $81.97 | 4.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.23 | 4.5% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.74 | 3.8% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $65.14 | 3.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $60.33 | 3.5% | 3 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $53.06 | 3.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.37 | 2.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.91 | 2.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29.37 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $24.16 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.52 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.54 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.59 | 1.0% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $16.37 | 1.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.09 | 0.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.08 | 0.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.99 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.57 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,710.14 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $286.46 | 14 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $213.82 | 18 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $186.67 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.37 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $138.83 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $138.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $109.25 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.68 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $79.33 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $76.23 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $67.54 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $65.74 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $65.14 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $60.33 | 3 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $53.06 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 113 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 332 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
113 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
332 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
332 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
142 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1285 | 90 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 2903 | 259 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2635 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 1501 | 143 |
| Furosemide | Furosemide | 1487 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1373 | 121 |
| Potassium Chloride | Potassium Chloride | 1325 | 121 |
| Gabapentin | Gabapentin | 1299 | 134 |
| Eliquis | Apixaban | 1285 | 90 |
| Donepezil Hcl | Donepezil Hcl | 1254 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 1226 | 157 |
| Losartan Potassium | Losartan Potassium | 1193 | 128 |
| Omeprazole | Omeprazole | 1119 | 148 |
| Lisinopril | Lisinopril | 997 | 122 |
| Metoprolol Tartrate | Metoprolol Tartrate | 993 | 67 |
| Sertraline Hcl | Sertraline Hcl | 990 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 948 | 93 |
| Duloxetine Hcl | Duloxetine Hcl | 830 | 61 |
| Mirtazapine | Mirtazapine | 800 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 796 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 669 | 97 |
| Trazodone Hcl | Trazodone Hcl | 652 | 55 |
| Alprazolam | Alprazolam | 648 | 103 |
| Carvedilol | Carvedilol | 635 | 46 |
| Simvastatin | Simvastatin | 611 | 69 |
| Buspirone Hcl | Buspirone Hcl | 607 | 38 |
| Famotidine | Famotidine | 571 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 539 | 34 |
| Tramadol Hcl | Tramadol Hcl | 537 | 85 |
| Memantine Hcl | Memantine Hcl | 507 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 469 | 72 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 462 | 25 |
| Januvia | Sitagliptin Phosphate | 430 | 29 |
| Metformin Hcl | Metformin Hcl | 427 | 57 |
| Allopurinol | Allopurinol | 421 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 408 | 55 |
| Lorazepam | Lorazepam | 368 | 53 |
| Montelukast Sodium | Montelukast Sodium | 360 | 39 |
| Prednisone | Prednisone | 360 | 109 |
| Jardiance | Empagliflozin | 332 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 330 | 14 |
| Levetiracetam | Levetiracetam | 324 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 307 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 301 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 291 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 290 | 31 |
| Spironolactone | Spironolactone | 288 | 20 |
| Torsemide | Torsemide | 288 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 278 | 41 |
| Metformin Hcl Er | Metformin Hcl | 258 | 27 |
| Lamotrigine | Lamotrigine | 247 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 244 | 27 |
| Divalproex Sodium | Divalproex Sodium | 231 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 225 | 22 |
| Finasteride | Finasteride | 217 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 208 | 22 |
| Myrbetriq | Mirabegron | 200 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 199 | 11 |
| Glimepiride | Glimepiride | 191 | 37 |
| Ezetimibe | Ezetimibe | 182 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 179 | 25 |
| Risperidone | Risperidone | 169 | 15 |
| Pentoxifylline | Pentoxifylline | 167 | suppressed |
| Cephalexin | Cephalexin | 162 | 88 |
| Olanzapine | Olanzapine | 162 | suppressed |
| Clonazepam | Clonazepam | 160 | 27 |
| Valsartan | Valsartan | 158 | 26 |
| Pregabalin | Pregabalin | 145 | 14 |
| Trulicity | Dulaglutide | 142 | 15 |
| Sotalol | Sotalol Hcl | 141 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 137 | suppressed |
| Baclofen | Baclofen | 135 | 13 |
| Meloxicam | Meloxicam | 134 | 23 |
| Xarelto | Rivaroxaban | 133 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 132 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 127 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 127 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 15 |
| Atenolol | Atenolol | 119 | 27 |
| Nifedipine Er | Nifedipine | 115 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 113 | 23 |
| Cimetidine | Cimetidine | 112 | suppressed |
| Glipizide | Glipizide | 112 | suppressed |
| Belsomra | Suvorexant | 110 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 109 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 108 | suppressed |
| Enulose | Lactulose | 106 | 16 |
| Celecoxib | Celecoxib | 104 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 74 |
| Methenamine Hippurate | Methenamine Hippurate | 104 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 100 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 93 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 31 |
| Primidone | Primidone | 86 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 85 | 84 |
| Aripiprazole | Aripiprazole | 85 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 82 | 24 |
| Bupropion Xl | Bupropion Hcl | 82 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | suppressed |
| Levemir | Insulin Detemir | 78 | suppressed |
| Mounjaro | Tirzepatide | 75 | 16 |
| Carbamazepine | Carbamazepine | 74 | suppressed |
| Cefdinir | Cefdinir | 74 | 56 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 72 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 71 | 15 |
| Diazepam | Diazepam | 70 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 68 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 66 | 16 |
| Synthroid | Levothyroxine Sodium | 66 | 16 |
| Entresto | Sacubitril/Valsartan | 65 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 65 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 64 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 64 | 14 |
| Digoxin | Digoxin | 63 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 63 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 62 | suppressed |
| Novolog Flexpen | Insulin Aspart | 62 | 20 |
| Enalapril Maleate | Enalapril Maleate | 61 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 59 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 37 |
| Anastrozole | Anastrozole | 58 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 55 | 13 |
| Bupropion Hcl | Bupropion Hcl | 54 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 54 | 14 |
| Linzess | Linaclotide | 54 | suppressed |
| Ozempic | Semaglutide | 54 | 17 |
| Phenobarbital | Phenobarbital | 54 | suppressed |
| Sucralfate | Sucralfate | 54 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | suppressed |
| Latanoprost | Latanoprost | 53 | suppressed |
| Amoxicillin | Amoxicillin | 52 | 42 |
| Bicalutamide | Bicalutamide | 51 | suppressed |
| Invokana | Canagliflozin | 51 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 21 |
| Trimethoprim | Trimethoprim | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | suppressed |
| Fluconazole | Fluconazole | 50 | 35 |
| Lansoprazole | Lansoprazole | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 48 | suppressed |
| Nystatin | Nystatin | 47 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 31 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 46 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 46 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Methotrexate | Methotrexate Sodium | 45 | suppressed |
| Xifaxan | Rifaximin | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 13 |
| Leucovorin Calcium | Leucovorin Calcium | 44 | suppressed |
| Topiramate | Topiramate | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 36 |
| Timolol Maleate | Timolol Maleate | 42 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 39 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 38 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 37 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Lacosamide | Lacosamide | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 15 |
| Hydroxyurea | Hydroxyurea | 35 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 35 | 22 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Mirabegron Er | Mirabegron | 34 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 17 |
| Cefaclor | Cefaclor | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 29 |
| Metolazone | Metolazone | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 20 |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Entacapone | Entacapone | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Ramelteon | Ramelteon | 28 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 28 | suppressed |
| Dofetilide | Dofetilide | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Letrozole | Letrozole | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | 11 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 12 |
| Erythromycin | Erythromycin Base | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 20 | 16 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Cyclosporine | Cyclosporine | 18 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Tresiba | Insulin Degludec | 18 | suppressed |
| Azathioprine | Azathioprine | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Silodosin | Silodosin | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluorometholone | Fluorometholone | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Rinvoq | Upadacitinib | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,710.14 · 91 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GIMOTI, INTELLIS ADAPTIVESTIM, JARDIANCE, JOURNAVX, Kerendia, MOUNJARO, Ozempic, PROLIA, Paradise Ultrasound Renal Denervation System, QULIPTA, REXULTI, Rybelsus, VERQUVO, VOQUEZNA, VRAYLAR, VYNDAMAX, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error